VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age 18 years or older                              │ Age 18 years or older                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of venous leg ulcer(s), as clinically    │ Diagnosis of venous leg ulcer(s), as clinically    │     100 │
│ determined by the investigator by a positive       │ determined by the investigator by a positive       │         │
│ venous reflux test (venous refilling \<20 seconds) │ venous reflux test (venous refilling <20 seconds)  │         │
│ using Doppler ultrasound for at least 4 weeks      │ using Doppler ultrasound for at least 4 weeks      │         │
│ prior to screening day, which have not adequately  │ prior to screening day, which have not adequately  │         │
│ responded to conventional ulcer therapy            │ responded to conventional ulcer therapy            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Designated venous leg ulcer meets the following    │ Designated venous leg ulcer meets the following    │     100 │
│ criteria at both the screening and baseline        │ criteria at both the screening and baseline        │         │
│ visits. If the patient has multiple ulcers, at     │ visits. If the patient has multiple ulcers, at     │         │
│ least one ulcer must meet the following criteria   │ least one ulcer must meet the following criteria   │         │
│ at both the screening and baseline visits          │ at both the screening and baseline visits          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Present for at least 4 weeks                       │ Present for at least 4 weeks                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CEAP Classification Stage 6                        │ CEAP Classification Stage 6                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Viable, granulating wound (investigator            │ Viable, granulating wound (investigator            │     100 │
│ discretion)                                        │ discretion)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ulcers that extend through the epidermis but not   │ Ulcers that extend through the epidermis but not   │     100 │
│ through the muscle, tendon, or bone (Stage II or   │ through the muscle, tendon, or bone (Stage II or   │         │
│ III ulcers as defined by the IAET)                 │ III ulcers as defined by the IAET)                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female patients of childbearing potential must     │ Female patients of childbearing potential must     │     100 │
│ have a negative pregnancy test at screening and    │ have a negative pregnancy test at screening and    │         │
│ must agree to use hormonal contraceptive,          │ must agree to use hormonal contraceptive,          │         │
│ intrauterine device, diaphragm with spermicide,    │ intrauterine device, diaphragm with spermicide,    │         │
│ condom with spermicide, or abstinence throughout   │ condom with spermicide, or abstinence throughout   │         │
│ until 2 weeks after the last administration of     │ until 2 weeks after the last administration of     │         │
│ study drug                                         │ study drug                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Signed informed consent                            │ Signed informed consent                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Decrease in size of the designated target ulcer(s) │ Decrease in size of the designated target ulcer(s) │     100 │
│ by ≥ 30% during the 7-day screening period         │ by ≥ 30% during the 7-day screening period         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cannot tolerate or comply with compression therapy │ Cannot tolerate or comply with compression therapy │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ An ulcer which shows signs of severe clinical      │ An ulcer which shows signs of severe clinical      │     100 │
│ infection, defined as pus oozing from the ulcer    │ infection, defined as pus oozing from the ulcer    │         │
│ site                                               │ site                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ An ulcer positive for β-hemolytic streptococci     │ An ulcer positive for β-hemolytic streptococci     │     100 │
│ upon culture                                       │ upon culture                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The ulcer has \> 50% slough, significant necrotic  │ The ulcer has > 50% slough, significant necrotic   │     100 │
│ tissue, bone, tendon, or capsule exposure or       │ tissue, bone, tendon, or capsule exposure or       │         │
│ avascular ulcer beds                               │ avascular ulcer beds                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Is highly exuding (i.e. requires daily change of   │ Is highly exuding (i.e. requires daily change of   │     100 │
│ dressing)                                          │ dressing)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with active systemic infections           │ Patients with active systemic infections           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with clinically significant medical       │ Patients with clinically significant medical       │     100 │
│ conditions as determined by the investigator       │ conditions as determined by the investigator       │         │
│ including renal, hepatic, hematologic, neurologic  │ including renal, hepatic, hematologic, neurologic  │         │
│ or immune disease. Examples include but are not    │ or immune disease. Examples include but are not    │         │
│ limited to                                         │ limited to                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal blood biochemistry defined as 3 times     │ Abnormal blood biochemistry defined as 3 times     │     100 │
│ that of the upper limit of the normal range        │ that of the upper limit of the normal range        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of an active systemic or local cancer or  │ Presence of an active systemic or local cancer or  │     100 │
│ tumor of any kind (with the exception of non-      │ tumor of any kind (with the exception of non-      │         │
│ melanoma skin cancer)                              │ melanoma skin cancer)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with severe rheumatoid arthritis (with    │ Patients with severe rheumatoid arthritis (with    │     100 │
│ more than 20 persistently inflamed joints, or      │ more than 20 persistently inflamed joints, or      │         │
│ below lower normal limit blood albumin level, or   │ below lower normal limit blood albumin level, or   │         │
│ evidence of bone and cartilage damage on x-ray, or │ evidence of bone and cartilage damage on x-ray, or │         │
│ inflammation in tissues other than joints) and     │ inflammation in tissues other than joints) and     │         │
│ other collagen vascular diseases                   │ other collagen vascular diseases                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with active connective tissue disease     │ Patients with active connective tissue disease     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous or current radiation therapy or           │ Previous or current radiation therapy or           │     100 │
│ likelihood to receive this therapy during study    │ likelihood to receive this therapy during study    │         │
│ participation                                      │ participation                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing patients                       │ Pregnant or nursing patients                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known prior inability or unavailability to         │ Known prior inability or unavailability to         │     100 │
│ complete required study visits during study        │ complete required study visits during study        │         │
│ participation                                      │ participation                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant peripheral edema as per investigator's │ Significant peripheral edema as per investigator's │     100 │
│ discretion                                         │ discretion                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A psychiatric condition (e.g., suicidal ideation)  │ A psychiatric condition (e.g., suicidal ideation)  │     100 │
│ or chronic alcohol or drug abuse problem,          │ or chronic alcohol or drug abuse problem,          │         │
│ determined from the patient's medical history,     │ determined from the patient's medical history,     │         │
│ which, in the opinion of the investigator, may     │ which, in the opinion of the investigator, may     │         │
│ pose a threat to patient compliance                │ pose a threat to patient compliance                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of a platelet-derived growth factor within 28  │ Use of a platelet-derived growth factor within 28  │     100 │
│ days before screening                              │ days before screening                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any investigational drug or therapy within  │ Use of any investigational drug or therapy within  │     100 │
│ 28 days before screening                           │ 28 days before screening                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has any other factor which may, in the opinion of  │ Has any other factor which may, in the opinion of  │     100 │
│ the investigator, compromise participation and/or  │ the investigator, compromise participation and/or  │         │
│ follow-up in the study                             │ follow-up in the study                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HbA1c \> 9%                                        │ HbA1c > 9%                                         │      95 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hematocrit \< 0.30                                 │ Hematocrit < 0.30                                  │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin \< 10 g/dL                              │ Hemoglobin < 10 g/dL                               │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count \< 100,000                          │ Platelet count < 100,000                           │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Surface ulcer with an area \> 15cm2 post           │ Surface ulcer with an area > 15cm2 post            │      99 │
│ debridement                                        │ debridement                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ankle brachial pressure index \<0.65               │ Ankle brachial pressure index <0.65                │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal insufficiency as an estimated GFR which is   │ Renal insufficiency as an estimated GFR which is < │      99 │
│ \< 30 mL/min/1.7m2                                 │ 30 mL/min/1.7m2                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic insufficiency defined as total bilirubin   │ Hepatic insufficiency defined as total bilirubin > │      99 │
│ \> 2 mg/dL or serum albumin \< 25 g/L              │ 2 mg/dL or serum albumin < 25 g/L                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with systemic corticosteroids (\>15      │ Treatment with systemic corticosteroids (>15       │      99 │
│ mg/day), or current immunosuppressive agents       │ mg/day), or current immunosuppressive agents       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Is highly exuding (i.e. requires daily change of │      40 │
│                                   │ dressing)                                        │         │
╘═══════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.02564102564102
OverAll Ratio: 98.51282051282051
